RBC Capital Reiterates Sector Perform on Spruce Biosciences, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated a Sector Perform rating on Spruce Biosciences (NASDAQ:SPRB) and maintained a $2 price target.
August 13, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Gregory Renza has reiterated a Sector Perform rating on Spruce Biosciences and maintained a $2 price target.
The reiteration of a Sector Perform rating and maintenance of a $2 price target by RBC Capital suggests a neutral outlook for Spruce Biosciences. This indicates that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's view.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100